资料显示，通化金马药业集团股份有限公司位于吉林省通化市二道江区金马路999号，成立日期1993年2 月26日，上市日期1997年4月30日，公司主营业务涉及药品的研发、生产和销售。主营业务收入构成 为：生化药59.27%，中成药40.56%，原料药0.10%，其他0.07%。 通化金马所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：东北振兴、医疗美容、 民营医院、中药、原料药等。 1月6日，通化金马盘中上涨2.14%，截至13:34，报27.17元/股，成交2.78亿元，换手率1.07%，总市值 262.60亿元。 资金流向方面，主力资金净流出2788.41万元，特大单买入2492.26万元，占比8.98%，卖出3315.42万 元，占比11.94%；大单买入5862.41万元，占比21.12%，卖出7827.66万元，占比28.20%。 通化金马今年以来股价跌1.16%，近5个交易日跌4.06%，近20日跌6.63%，近60日涨7.48%。 分红方面，通化金马A股上市后累计派现2.10亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，通化金马十大流通股东中，创新药（ ...

截至9月30日，通化金马股东户数3.82万，较上期减少3.20%；人均流通股25266股，较上期增加3.31%。 2025年1月-9月，通化金马实现营业收入8.92亿元，同比减少7.88%；归母净利润2496.35万元，同比增长 4.35%。 分红方面，通化金马A股上市后累计派现2.10亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，通化金马十大流通股东中，创新药（159992）位居第七大流通股 东，持股919.30万股，相比上期增加8.78万股。南方中证1000ETF（512100）位居第八大流通股东，持 股884.16万股，相比上期减少9.23万股。香港中央结算有限公司位居第九大流通股东，持股726.71万 股，相比上期减少150.84万股。华夏中证1000ETF（159845）位居第十大流通股东，持股525.31万股， 为新进股东。 今年以来通化金马已经2次登上龙虎榜，最近一次登上龙虎榜为9月11日，当日龙虎榜净买入1.42亿元； 买入总计5.44亿元 ，占总成交额比29.22%；卖出总计4.02亿元 ，占总成交额比21.59%。 资料显示，通化金马药业集团股份有限公司位于吉 ...

Core Viewpoint - Tonghua Jinma's stock price has shown significant volatility, with a year-to-date increase of 76.31%, but a recent decline of 3.72% over the last five trading days [1] Group 1: Stock Performance - As of November 26, Tonghua Jinma's stock price was 27.68 CNY per share, with a market capitalization of 26.753 billion CNY [1] - The stock has experienced a trading volume of 73.0787 million CNY, with a turnover rate of 0.28% [1] - The company has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) twice this year, with the latest appearance on September 11, where it recorded a net buy of 142 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million CNY, a year-on-year decrease of 7.88%, while net profit attributable to shareholders was 24.9635 million CNY, an increase of 4.35% [2] - The company's main business revenue composition includes biopharmaceuticals (59.27%), traditional Chinese medicine (40.56%), raw materials (0.10%), and others (0.07%) [1] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tonghua Jinma was 38,200, a decrease of 3.20% from the previous period [2] - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with varying changes in their holdings [3]

Core Viewpoint - Tonghua Jinma's stock price has shown significant growth this year, with a year-to-date increase of 76.75%, despite a slight decline in the last five trading days [1][2]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million yuan, a year-on-year decrease of 7.88%, while the net profit attributable to shareholders increased by 4.35% to 24.96 million yuan [2]. - The company has cumulatively distributed 210 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of November 11, 2023, Tonghua Jinma's stock was trading at 27.75 yuan per share, with a market capitalization of 26.82 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent net purchase of 142 million yuan on September 11 [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders was 38,200, a decrease of 3.20% from the previous period, with an average of 25,266 circulating shares per shareholder, an increase of 3.31% [2][3]. - Notable shareholders include Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings compared to the previous period [3].

Core Insights - Tonghua Golden Horse's stock price increased by 2.13% on October 31, reaching 25.85 CNY per share, with a total market capitalization of 24.984 billion CNY [1] - The company has seen a year-to-date stock price increase of 64.65%, with a recent 5-day increase of 2.58% [1][2] - For the first nine months of 2025, the company reported a revenue of 892 million CNY, a year-on-year decrease of 7.88%, while net profit attributable to shareholders increased by 4.35% to 24.9635 million CNY [2][3] Financial Performance - The company’s main business revenue composition includes biopharmaceuticals (59.27%), traditional Chinese medicine (40.56%), raw materials (0.10%), and others (0.07%) [1] - As of September 30, 2025, the number of shareholders decreased by 3.20% to 38,200, with an average of 25,266 circulating shares per shareholder, an increase of 3.31% [2] Shareholder Structure - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings noted [3] - Cumulative cash dividends since the company's A-share listing amount to 210 million CNY, with no dividends paid in the last three years [3]

Core Viewpoint - Tonghua Jinma's stock price has shown a significant increase of 56.56% year-to-date, but has recently experienced a slight decline in the last few trading days [1][2]. Financial Performance - For the first half of 2025, Tonghua Jinma achieved a revenue of 650 million yuan, reflecting a year-on-year growth of 0.12%. The net profit attributable to shareholders was 16.80 million yuan, marking a substantial increase of 34.77% [2]. - The company has cumulatively distributed 210 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of October 16, the stock price was 24.58 yuan per share, with a market capitalization of 23.756 billion yuan. The trading volume was 184 million yuan, with a turnover rate of 0.77% [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on September 11, where it saw a net purchase of 142 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 39,500, a rise of 6.54%. The average number of tradable shares per shareholder decreased by 6.13% to 24,457 shares [2]. - Notable shareholders include Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings reported [3].

Group 1 - The core viewpoint of the news is that Tonghua Jinma has shown significant stock performance and financial growth, with a notable increase in share price and market capitalization [1][2]. - As of September 30, Tonghua Jinma's stock price increased by 64.46% year-to-date, with a market capitalization of 24.955 billion yuan [1]. - The company has experienced a net inflow of main funds amounting to 4.2117 million yuan, with significant buying activity from large orders [1]. Group 2 - Tonghua Jinma's main business revenue composition includes 59.27% from biochemical drugs, 40.56% from traditional Chinese medicine, and minimal contributions from raw materials and others [1]. - For the first half of 2025, Tonghua Jinma reported an operating income of 650 million yuan, reflecting a year-on-year growth of 0.12%, and a net profit attributable to shareholders of 16.804 million yuan, up 34.77% [2]. - The company has not distributed dividends in the last three years, with a total payout of 210 million yuan since its A-share listing [3].

Group 1 - The core viewpoint of the news is the performance and financial metrics of Tonghua Jinma Pharmaceutical Group Co., Ltd, highlighting its stock price increase and market capitalization [1] - As of September 11, Tonghua Jinma's stock rose by 5.03%, reaching a price of 26.29 yuan per share, with a trading volume of 1.584 billion yuan and a turnover rate of 6.61%, resulting in a total market value of 25.409 billion yuan [1] - The company, established on February 26, 1993, and listed on April 30, 1997, focuses on the research, production, and sales of pharmaceuticals, with its main revenue sources being biopharmaceuticals (59.27%), traditional Chinese medicine (40.56%), raw materials (0.10%), and others (0.07%) [1] Group 2 - From the perspective of fund holdings, Guolian An Fund has a significant position in Tonghua Jinma, with its Guolian An CSI Pharmaceutical 100A fund holding 96,800 shares, accounting for 1.04% of the fund's net value [2] - The fund reduced its holdings by 47,600 shares in the second quarter, and the estimated floating profit from this investment is approximately 122,000 yuan [2] - The Guolian An CSI Pharmaceutical 100A fund, established on August 21, 2013, has a current scale of 178 million yuan, with a year-to-date return of 20.34% and a one-year return of 38.85% [2]